You are here

omburtamab

Y-mAbs' rare disease drug roundly rejected by FDA AdComm over weakness of single-arm trial

Fierce Biotech

Mon, 10/31/22 - 10:27 am

Y-mAbs Therapeutics

pediatric neuroblastoma

FDA Guidance Raises Concerns about Y-mAbs’ Neuroblastoma Treatment before Adcomm

BioSpace

Thu, 10/27/22 - 10:59 am

Y-mAbs Therapeutics

Y-mAbs pushes back re-submission of its neuroblastoma BLA to end of 2021

Endpoints

Wed, 06/23/21 - 10:41 am

Y-mAbs Therapeutics

FDA hands Y-mAbs refusal to file letter in one of its pediatric neuroblastoma programs

Endpoints

Tue, 10/6/20 - 10:54 am